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ABSTRACT
Chordoma is a rare malignant tumor that recapitulates the notochord phenotype 
and is thought to derive from notochord remnants not correctly regressed during 
development. Apoptosis is necessary for the proper notochord development 
in vertebrates, and the apoptotic pathway mediated by Fas and Fasl has been 
demonstrated to be involved in notochord cells regression. This study was conducted 
to investigate the expression of FAS/FASL pathway in a cohort of skull base chordomas 
and to analyze the role of fas/fasl homologs in zebrafish notochord formation.  
FAS/FASL expression was found to be dysregulated in chordoma leading to inactivation 
of the downstream Caspases in the samples analyzed. Both fas and fasl were 
specifically expressed in zebrafish notochord sorted cells. fas and fasl loss-of-function 
mainly resulted in larvae with notochord multi-cell-layer jumps organization, larger 
vacuolated notochord cells, defects in the peri-notochordal sheath structure and in 
vertebral mineralization. Interestingly, we observed the persistent expression of ntla 
and col2a1a, the zebrafish homologs of the human T gene and COL2A1 respectively, 
which are specifically up-regulated in chordoma. These results demonstrate for the 
first time the dysregulation of FAS/FASL in chordoma and their role in notochord 
formation in the zebrafish model, suggesting their possible implication in chordoma 
onset.
INTRODUCTION
Chordoma is a rare slow-growing malignant tumor 
of notochordal origin. Chordoma can localize at Skull 
Base (SBC), sacral or spinal axis level, and accounts 
for approximately 0.1%–0.25% of intracranial tumors 
and 1%–4% of all malignant bone tumors [1, 2]. The 
treatment of choice for these tumors is en-bloc resection 
followed by postoperative radiation therapy [3]. To date 
chordoma is considered unresponsive to chemotherapy 
and no validated molecular markers are available to 
monitor the tumor progression [3]. Several line of 
evidences suggest that chordoma is characterized by 
abnormal regulation of notochord tissue. Histological 
studies have identified persistence of notochord tissue 
in this tumor that is localized along the axial skeleton, 
and expresses transcription factors that are also expressed 
in the notochord. Among them, the most significant is 
the transcription factor T (encoding for Brachyury), 
the founder member of the T-box family involved in 
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notochord development [4-6], and recently identified as 
the pathognomonic marker for chordoma [7]. The genetic 
basis of T expression in chordoma is largely unknown 
[7-9], thus the question concerning the identification 
of early tumorigenic mechanisms leading to chordoma 
remains open and further pathways should be considered. 
Indeed, in a recent study other genes were found 
differentially expressed in both chordomas and related 
cell lines, among them the α1 collagen type II (COL2A1) 
was significantly over-expressed [10].
The proper balance between notochord cell 
proliferation and apoptosis seems to be fundamental 
for the development and regression of the notochord. 
The apoptotic process is involved in normal notochord 
development in Xenopus laevis [11], and in particular the 
extrinsic apoptotic pathway is conserved and necessary for 
notochord development in zebrafish [12]. In addition, the 
expression of tumor necrosis factor receptor (TNFR) FAS 
and its ligand FASL, leads to the notochord cells regression 
in the adult rat intervertebral disks [13, 14]. The autocrine-
paracrine interaction between Fas and Fasl results in the 
trimerization and activation of the Fas receptor, which 
leads the cell to apoptosis [15, 16]. Multiple mechanisms 
regulate the sensitivity of Fas-expressing cells to Fas-
induced apoptosis, including alternative splicing of FAS 
pre-mRNA: mRNAs lacking exon 6 encode soluble 
forms of the receptor which, sequestering Fasl, lead to 
a reduction of Fas signaling, inhibiting apoptosis [17]. 
Although molecular functions of Fas and Fasl are well 
known, their role during notochord development has 
never been investigated in full. Since fas and fasl showed 
conserved synteny between fish and mammals and also 
their functional domains are conserved [12], zebrafish 
(Danio rerio) represents a suitable animal model for 
functional studies.
The zebrafish notochord starts to form during 
gastrulation [18] and expresses brachyury (ntl) [19], 
sonic-hedgehog (shh) [20], and later α1-collagen 
Type II (col2a1) [21]. During the segmentation period, 
central cells of the notochord differentiate, acquiring a 
large vacuole and the notochord becomes surrounded by 
a sheath of tissue which, in combination with the turgor 
pressure generated by the vacuolated cells, imparts to the 
notochord its stiffness [22]. The differentiation correlates 
to apoptotic events that in the zebrafish happen between 
14 and 24 hours post fertilization (14-24 hpf) [23]. As 
notochord cells become vacuolated, the expressions of ntl, 
shh and col2a1 are extinguished in the notochord [19], 
while shh is maintained in the floor plate and col2a1 in the 
floor plate and the perinotochordal sheath [21, 24].
Here we report the expression analysis of FAS and 
FASL and their downstream effectors Caspase 8 and 
Caspase 3 in a cohort of SBC samples, and functional 
studies of fas and fasl homologs genes during notochord 
formation in the zebrafish model. The obtained results 
indicate that FAS/FASL expression is dysregulated in 
chordoma and that the downstream Caspase 8 and 3 
are mostly inactive in the SBCs analyzed. Moreover, 
simultaneous knock-down of fas and fasl in zebrafish 
resulted in defects during notochord formation and 
in vertebral mineralization. Interestingly, we also 
observed the maintenance of the expression of ntla and 
col2a1a, the zebrafish homologs of the human T gene 
and COL2A1, which were found to be specifically up-
regulated in chordoma [10]. The obtained evidence 
strongly supports the implication of FAS/FASL in 
chordoma tumorigenesis.
RESULTS
FAS/FASL pathway is inactivated in SBCs
In our study we used SBCs samples that were 
validated at molecular level as bona fide SBCs samples. 
We also analyzed, by RT-PCR, the expression of the 
T gene in all the SBCs samples and U-CH1 chordoma cell 
line we used. In agreement with literature [10] T gene was 
expressed in all the samples. (Supplementary Material, 
Suppl. Fig. S1 A), while a pool of three Nuclei Pulposi 
(NP), commonly accepted as the reference control tissue 
for chordoma tumor since it is the only adult tissue of 
notochordal origin [25-28], was not expressing T gene. 
Western blot analysis, performed in a sub-group of twelve 
tumors and in U-CH1 cells, revealed the expression of 
Brachyury in all the samples analyzed, confirming the RT-
PCR results (Suppl. Fig. S1 B) and the previous chordoma 
diagnosis obtained by immunohistochemistry (data not 
shown).
The transcription of FAS and FASL genes was 
studied by means of RT-PCR in the pull of NP, in thirty-
four SBCs samples and in U-CH1 cells. Most of the 
analyzed samples (82%) showed FAS expression, while 
FASL transcript was present in only 38% of samples and 
U-CH1 cell line expressed both genes (Fig. 1 A). In order 
to determine the status of activation of Fas/Fasl apoptotic 
pathway in chordoma, we checked for the expression 
of the two different isoforms of FAS: the pro-apoptotic 
(transmembrane) form and the anti-apoptotic (soluble) 
form [29] by RT-PCR, in the sub-group of 12 tumors 
and in U-CH1 cells (Fig. 1 B). Interestingly, all the SBCs 
samples and the U-CH1 cells showed the expression of 
both, the transmembrane pro-apoptotic and the soluble 
anti-apoptotic, isoforms of FAS, while NP showed the 
solely expression of the pro-apoptotic transmembrane 
isoform (Fig. 1 B).
We also determined, in the same samples, the 
presence of Fas, Fasl Caspase 8 and Caspase 3 proteins 
by western blot analysis. We found the inactive Caspase 8 
(pro Caspase 8) to be expressed in all the samples 
analyzed, while the active form (pre Caspase 8) was 
found weakly expressed only in 3 tumors (Fig. 1 C). 
The inactive form of pre Caspase 3 was detected in 
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83% of the samples (10/12 samples) (Fig. 1 C). These 
results suggest a specific role for the anti-apoptotic Fas 
in blocking the Caspase cascade and consequently the 
apoptotic pathway in chordoma samples and UCH1 cell 
line. To verify if the expression of anti-apoptotic Fas 
is responsible for this state, we exposed U-CH1 cells 
to synthetic soluble Fasl (SuperFAS Ligand), which 
is able to induce apoptosis by competing with the anti-
apoptotic (soluble) isoform of Fas. The amount of Pro 
caspase 8 and of Pre Caspase 8 were evaluated by means 
of western blot analysis following soluble Fasl treatments 
at different concentrations and times of exposures. 
Figure 1: Expression analysis of FAS, FASL and effector Caspase 8 and 3 in a cohort of SBCs and U-CH1 cell line. 
(A) RT-PCR results of FAS and FASL in 34 SBCs, Nuclei Pulposi (NP) and U-CH1 cell line; black dots indicate gene expression; white dots 
indicate no gene expression; (B) RT-PCR of antiapoptotic soluble FAS (sol FAS) and proapototic transmembrane FAS (tm FAS) in 12 SBCs, 
Nuclei Pulposi (NP) and U-CH1 cell line; NC indicates the RT-PCR negative control; (C) western blots of Fas, Fasl, Pro Caspase 8 (pro 
Casp8), Pre Caspase 8 (pre Casp8) and Pro Caspase 3 (pro Casp3) in 12 SBCs and U-CH1 cell line; the α β Tubulin (α β tub) was included 
as a housekeeping protein expression. (D) Western blot analysis of Pro caspase 8 (pro casp8), Pre caspase 8 (pre casp8) and α β Tub 
following U-CH1 cell line treatments with soluble FasL. U-CH1 were treated with soluble Fasl at the doses of 0 ng/mL (untreated control), 
30 and 100 ng/mL for 24 and 48 hours, left and right panel respectively. (E) Quantification of relative Pro casp 8 expression levels after 
normalization to α β tub in U-CH1 cells trated with Fasl, the white bars represent expression level of Pro casp 8. (F) Quantification of 
relative Pre casp 8 expression levels after normalization to α β tub in U-CH1 cells trated with Fasl, gray bars indicate the level of Pre casp 8. 
(G) Representation of the quantification of relative Pro casp 8 and of Pre casp 8 expression levels after normalization to α β Tub divided 
for each concentration, white bars indicate Pro casp 8 in U-CH1 cells treated with Fasl for 24 hours, white-dithered bars indicate Pre casp 8 
treated with Fasl for 24 hours, gray bars indicate Pro casp 8 of Fasl for 48 hours, gray-dithered bars indicate Pre casp 8 treated with Fasl for 
48 hours. (H) Ratios between Pre casp 8 and Pro casp 8 after treatments, the black bars represent the ratio for each treatment concentration 
at each time of exposure. (D-G) The data are expressed as fold increase over the untreated control (0 ng/mL); *p<0,05.
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After Fasl treatments the levels of Pre caspase 8 
significantly increased together with the significant 
decrease of Pro Caspase 8 levels in a dose and time 
exposure dependent manner (Fig. 1 D-G). Moreover, the 
ratio between Pre Caspase 8 and Pro Caspase 8 increased 
in a dose and time dependent manner (Fig. 1 H). These 
findings indicate that the administration of Fasl in U-CH1 
cell line is able to counteract the role of the anti-apoptotic 
form of Fas and induces the apoptotic pathway via Pro 
Caspase 8, suggesting that this pathway can be modulated 
in this tumor.
Zebrafish fas and fasl expression and function
Previous studies show contrasting results on the 
expression of fas and fasl in the zebrafish. Some reported 
that fas and fasl expression were not seen by whole-mount 
in situ hybridization (WISH) during the first stages of 
development [12], while in some cases their transcripts 
were detected by RT-PCR [12]. To clarify this point, 
we performed RT-PCR analyses of zebrafish fas and 
fasl in the whole developing embryo, larva and in some 
selected adult tissues (Fig. 2 A). We determined that fas is 
expressed in all the analyzed developmental stages, while 
fasl expression is modulated during development showing 
an initial maternal expression, fasl transcripts disappeared 
in the zygotic stages (30% epiboly-somites stages) to 
return at 24 hpf. To specifically analyze the expression 
of fas and fasl in the notochord, we labeled notochord 
cells by injected the pCS2+ (twhh:GFP) construct [30] 
and FACS-sorted GFP+ cells from embryos at 24 and 
48 hpf, the GFP+ cells were then analyzed by RT-PCR. 
Expression of fas was detected in the notochord cells 
at both 24 and 48 hpf, while fasl was expressed only at 
48 hpf (Fig. 2 B). Thus, like for the SBCs, in zebrafish 
embryogenesis the expression of fas is constant, while fasl 
transcription is modulated in time.
To investigate the function of fas and fasl in 
zebrafish development, we knocked-down these genes 
using oligonucleotide-antisense morpholinos (MO). 
As a control we injected a non-specific control MO 
(ctrl-MO). The single fas-MO and fasl-MO injection 
(0,7 pmol/embryo), or co-injection of fas/fasl-MO at a 
dosage that did not individually cause morphological 
defects (0,5 pmol/embryo/each) presented the same 
defective phenotypes. Therefore, for all the following 
results, we decided to present the data of the double 
knock-down (fas/fasl-MO) (Fig. 2 C). The fas/fasl-loss-of-
function phenotype was characterized by bent notochord, 
curved tail and cephalic and cardiac edema (60% N=620, 
Fig. 2 D-G’), that was worsening during later stages of 
development. In addition, from 3 dpf, the most evident 
defect in fas/fasl-MO injected embryos was a high 
reduction in motility. The ctrl-MO injected larvae, when 
stimulated with the touch response assay, escaped in the 
opposite direction (100% N=50, Movie 1) while fas/fasl-
MO injected larvae were characterized by an altered 
motility, swimming in circle (80% N=80, Movie 2). 
Following the injection of fasl mRNA in fasl-MO injected 
larvae, we were able to rescue the phenotype, confirming 
the specificity of the down-regulation (80% N=65, 
Movie 3). The in-vivo efficiency of the ATG morpholinos 
Figure 2: Expression and functional analysis of fas and fasl in zebrafish. (A) RT-PCR performed on different developmental 
stages and adult tissues. fas is expressed in all the analyzed developmental stages, fasl presents a maternal expression, while the zygotic 
expression starts from 24 hpf. Both genes are expressed in all the adult tissues analyzed. (B) PCR performed on cDNA of the notochord 
cells sorted from embryos at 24 and 48 hpf injected with the twhh:GFP/PCS2+ construct. fas is expressed in the notochord cells at both 
24 and 48 hpf, while fasl only at 48 hpf. (C) Injected embryos for the single or double knock-down of fas and fasl and for the rescue of the 
phenotype, were analyzed by scoring the presence/absence of curved bodies and cardiac edema and subdivided into phenotypic classes. 
(D-G) Embryos and larvae injected with ctrl-MO exhibit normal development at 24 hpf (D), 48 hpf (E), 3 dpf (F) and 5 dpf (G). (D’-G’) 
Embryos and larvae co-injected with fas/fasl-MO develop defects in the tail curvature due to notochord distortion and cardiac edema. This 
phenotype is worsening during development.
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was tested with sensor plasmids (Supplementary Material, 
Suppl. Fig. S2 A-B’, D-E’). Moreover, we designed splice-
site morpholinos (splice-fas-MO and splice-fasl-MO; 
1 pmol/embryo/each) that presented consistent phenotypes 
with the ATG morpholinos (80% altered motility N=400, 
55% bent notochord, curved tail and cephalic and cardiac 
edema, N=320), confirming the specificity of the loss-of-
functions. The efficiency of the splice-site-MOs was tested 
by means of RT-PCR (Supplementary Material, Suppl. 
Fig. S2 C,F).
fas/fasl-MO-injected embryos share similarities 
with chordoma tumors
The most direct readout for the knock-down of the 
apoptotic genes fas/fasl is a decrease in apoptosis. Thus, 
we performed TUNEL assay at different developmental 
stages. To exclude undesirable off-target effects elicited 
by the injection of morpholino molecules, such as 
activation of the p53 protein [31], we injected p53-MO 
together with fas/fasl-MO and with control-MO. We 
observed that apoptosis was reduced in fas/fasl/p53-MO 
injected embryos compared to the control/p53-MO at the 
same developmental stages (50% N=60, Supplementary 
Material, Suppl. Fig. S3).
Next, we sought to analyze the expression 
profile of the genes that have been found altered in the 
chordoma tumors, such as the T gene and COL2A1. Both 
the zebrafish homolog ntla and col2a1a were found to 
be significantly up-regulated in fas/fasl-MO-injected-
embryos by qPCR analyses (p≤0,05) (Fig. 3 A-B). These 
results were confirmed by WISH analyses. The expression 
of ntla, that normally progressively decays from 20 hpf, 
was maintained at high levels in fas/fasl-MO injected 
embryos (50% of fas/fasl-MO-injected, total N= 30) 
(Fig. 3 C-D). Moreover, the expression of col2a1a, that 
normally diminished from 30 hpf and disappeared at 
48 hpf [21, 32], persisted in the peri-notochordal sheath 
in fas/fasl-MO injected embryos at 48 hpf (70% of fas/
fasl-MO-injected, total N= 60) (Fig. 3 E-F).
Figure 3: ntla and col2a1a are up-regulated in fas/fasl-MO injected embryos. (A-B) q-PCR analysis of ntla (A) and col2a1a 
(B) show an upregulation of the expression in fas/fasl-MO injected embryos for both genes (*p≤0,05). (C-D) WISH analysis show 
persistent expression of the notochord marker ntla in the notochord of fas/fasl-MO injected embryos at 24 hpf (D) compared to control 
embryos (C). (E-F) WISH analysis shows persistent expression of the chordamesoderm marker col2a1a in the peri-norochordal sheath of 
fas/fasl-MO injected embryos (F, arrowheads) compared to control embryos in which col2a1a expression normally decreases at 48 hpf 
(E, arrowheads).
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Notochord architecture and surrounding tissues 
are affected in fas/fasl-MO injected larvae
fas and fasl are expressed in the notochord, 
thus we analyzed possible defects caused by fas/fasl- 
loss-of-function in this structure and in the sur-
rounding tissues. Taking advantage of the ET30: 
Et(kita:GalTA4,UAS:mCherry)hzm (ET30) transgenic 
line, where the fluorescent protein mCherry is expressed 
in notochord cells [33, 34], we were able to analyze 
the morphology of the notochord. Notwithstanding the 
curved tails and the notochord bents observed in fas/fasl-
MO injected embryos starting from 24 hpf, no evident 
morphological defects in the notochord cells were shown 
before 48 hpf (data not shown). However, later during 
development (i.e. 4 dpf), the fas/fasl-MO injected larvae 
(80%, N=70) presented notochord undulations and multi-
cell-layer jumps (Fig. 4 B) instead of the characteristic 
single “stack-of-coins” structure seen on ctrl-MO injected 
larvae (N=70) (Fig. 4 A). Moreover, longitudinal sections 
of fas/fasl-MO injected larvae at 4 dpf showed that the 
entire notochord structure was bigger in comparison to 
ctrl-MO injected larvae and the larger vacuolated cells 
were not properly connected to the peri-notochordal 
sheath, indicative of a failure of the cells to differentiate 
(Fig. 4 C-D). Indeed, the peri-notochordal basement 
membrane of fas/fasl-MO injected larvae at 4 dpf, was 
abnormally undulated and thicker than the ctrl-MO 
injected larvae, in particular in areas where the profile of 
the notochord is bent (Fig. 4 C-D). The phenotypic defects 
in notochord structure are specifically caused by fas/fasl-
loss-of-function as rescued larvae (75% N=120) did not 
present such defects (Supplementary material, Suppl. Fig. 
S4 A-C). We considered the possibility that the defects in 
notochord morphology might have resulted from a general 
developmental delay, although fas/fasl-loss-of-function 
embryos did not differ noticeably in overall development 
from ctrl-MO. To verify this hypothesis we compared the 
vessels formation in ctrl-MO and fas/fasl-MO injected 
larvae using Tg(flk1:EGFP) fish line. In both cases, vessels 
formation at 4 dpf was comparable, (control N=40; fas/
fasl-MO N=40) [35], as shown in the Suppl. Fig. S5, 
indicating that both ctrl-MO and fas/fasl-MO injected 
larvae were at the same developmental stage.
Muscle organization and primary motoneuron 
axonal projections are altered in fas/fasl-MO 
injected larvae
The impaired motility of fas/fasl-MO injected 
larvae from 3 dpf, prompted us to analyze the muscle 
structure by means of histological sections: at 4 dpf 
fas/fasl-MO injected larvae showed muscles with a 
disorganized alignment of myofibrils that appeared 
undulated and unusually oriented (80% N=40) compared 
to the controls (N=40) (Fig. 5 A-B). Motility impairment 
could be due to motoneuron defects, thus we analyzed 
primary motoneurons and their axon (visualized by 
the znp1 antibody); they formed in a proper number 
and position in fas/fasl-MO injected embryos (N=30) 
Figure 4: fas and fasl loss-of-function affects notochord differentiation and peri-notochordal sheath integrity. (A-B) 
Confocal images of the mCherry-positive-notochord cells of the ET30 transgenic line at 4 dpf. In ctrl-MO injected larvae (A), the notochord 
shows its characteristic “stack-of-coins” structure while fas/fasl-MO injected larvae (B) present notochord undulations and form multi-
cell-layer jumps. The same region of the notochord has been analyzed in ctrl-MO and fas/fasl-MO injected larvae, as shown by the yolk 
extension. (A-B) Squared brackets indicate the diameter of the notochord. (C-D) Longitudinal sections hematoxilin-eosin (HE) stained of 
ctrl-MO and fas/fasl-MO injected larvae at 4 dpf. The notochord (n) of morphants is thicker, and vacuolated cells are not properly connected 
to the peri-notochordal sheat that is abnormally undulated (arrowheads, D), in comparison to ctrl-MO injected larvae (C). (A-D) lateral 
views, anterior to the left, dorsal up. Scale bars: (A-B) 100 μm, (C-D) 50 μm.
Oncotarget5718www.impactjournals.com/oncotarget
Figure 5: Defects in notochord differentiation prevent normal muscle structure and primary motoneuron axon 
projections. (A-B) Longitudinal histological sections, HE stained. At 4 dpf, muscle fibres in fas/fasl-MO injected larvae are disorganized, 
undulated and oriented in opposite directions (B, arrowheads) in comparison to ctrl-MO injected larvae (A). (C-D) Axonal projections of 
primary motoneurons visualized by znp1 antibody present branching defects in fas/fasl-MO injected embryos at 24 hpf (arrows). (A-D) 
lateral views, anterior to the left, dorsal up. Scale bar: 100 μm.
at 24 hpf compared to the controls (N=30). However, 
the disorganization in muscle and myosepta caused a 
disorganized branching of axonal projections (Fig. 5 C-D). 
Rescued larvae (89% N=170 for muscle defects, 
Supplementary material, Suppl. Fig. S4 D-F; 75% N=80 
for motoneuron defects, Supplementary material, Suppl. 
Fig. S4 G-I) did not present such defects.
Notochord defects in fas/fasl-MO injected larvae 
lead to abnormal vertebral development
Several evidences suggest that the notochord has 
been directly implicated in the formation of vertebrae and 
intervertebral discs [36, 37]. Therefore, we verified whether 
defects in notochord differentiation in fas/fasl-MO injected 
larvae could influence subsequent vertebral formation. 
We calcein stained fas/fasl-MO injected larvae at early 
(13 dpf, around 5 mm, Fig. 6 A-B’) and complete vertebral 
mineralization (18 dpf, around 7-9 mm, Fig. 6 C-E) and 
we showed defects in vertebrae formation with extensive 
vertebrae fusion (15% N=30, Fig. 6 B,B’,D) in comparison 
to ctrl-MO injected larvae (0% N=30, Fig. 6 A,A’,C). Also 
the defects in vertebrae mineralization are specifically 
caused by fas/fasl-loss-of-function as the majority of 
rescued larvae did not present such defects (79% N=28), 
(Supplementary material, Suppl. Fig. S4 J-L).
DISCUSSION
Chordoma is a rare malignant tumor that is thought 
to arise from notochord remnants. The notochord regression 
is regulated by several mechanisms, and among them, 
the apoptotic process plays a relevant role [11, 38, 39]. 
Figure 6: Analyses of notochord segmentation and vertebral formation following fas/fasl loss of function. (A-D) Calcein 
staining shows notochord segmentation by formation of calcified chordacentra in an antero-posterior fashion. The process of vertebrae 
formation starts at around 11 dpf (3 mm) and is completed at around 18-21 dpf (7-9 mm). fas/fasl-MO-injected larvae at early (B-B’ higher 
magnification) and complete vertebral mineralization (D) show significant defects in vertebrae formation with extensive vertebrae fusion 
(arrows, D) in comparison to ctrl-MO injected larvae (A, A’ higher magnification, C). Scale bar: 100 μm.
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In particular, the Fas/Fasl pathway was implicated 
in the regression of the notochord cells during adult 
nucleus pulposus formation in rat [13]. In this work, we 
demonstrated for the first time that FAS/FASL expression 
was dysregulated in chordoma, mainly for the absence of 
FASL. Furthermore, all SBC specimens and the U-CH1 
cell line, including those expressing FASL, showed the 
expression of the FAS soluble anti-apoptotic isoform 
that was not detected in the reference tissue of NP. It 
is known that the soluble anti-apoptotic form of Fas 
competes with the transmembrane pro-apoptotic form 
in binding FASL and therefore inhibits apoptosis [17]. 
The prevalent expression of the inactive form of the 
downstream effectors Caspase 8 and Caspase 3 confirmed 
the inactivation status of the related apoptotic pathway 
in the SBCs analyzed. We were able to revert this status 
in U-CH1 cells by exposition to synthetic soluble Fasl, 
activating Caspase 8 in a time and dose dependent manner, 
showing that, in vitro chordoma cell line, the FAS/FASL 
pathway can be modulated.
The expression studies performed in our cohort of 
SBCs suggest a possible involvement of FAS and FASL in 
chordoma onset. However, from in vitro and chordoma 
samples we could not determine if this genetic expression 
profile is the cause or the result of the SBC [7]. Aiming 
to elucidate this ontological question of cancer etiology, 
we began to investigate the effects of the dysregulation 
of FAS/FASL in notochord during embryo development. 
We performed functional assays in the zebrafish model. 
We firstly evaluated the expression of fas and fasl in 
zebrafish whole embryos and larvae. The expression of 
fas and fasl in brain, eyes, gut and ovary of the adult fish 
is conserved in mammals, indicating a similar role for 
FAS/FASL during evolution [14, 40-43]. Interestingly, 
fasl expression is modulated during development while 
fas is expressed in all stages analyzed, suggesting 
the importance of a specific activation of this factor. 
Moreover, we detected fas and fasl expression in the 
zebrafish notochord sorted cells, pinpointing for the first 
time the involvement of these two genes in the processes 
of notochord formation.
By using morpholino technology, we performed 
loss-of-function experiments to analyze notochord 
defects in zebrafish embryos and larvae. As expected, 
a reduction of apoptosis was observed in fas/fasl-MO 
injected embryos. In addition, we found a significant 
up-regulation of two homologs of chordoma markers, 
ntla (T) and col2a1a (COL2A1) [10]. The maintained 
expression of these two genes in fas/fasl-MO-injected 
embryos in a developmental stage in which they normally 
diminished and disappeared, might suggest molecular 
alteration common to chordoma. The up-regulation 
of the col2a1a, as well as deregulation of other genes 
expressed in the notochord or in the perinotochordal 
sheath, such as col15a1, col27a1a and col27a, are linked 
to defects of the notochord sheath and aggregation of 
protein in notochord cells, as demonstrated in previous 
reports [44, 45]. Consistently with these works, we 
found severe alterations of the notochord morphology 
that presented various degrees of packed cells that were 
larger and not properly connected to the perinotochordal 
sheath. In addition, the loss-of-function of fas/fasl 
produced disorganized myofibrils and an aberrant primary 
motoneurons branching, resulting in motility impairment. 
Indeed, both muscle and motoneuron formation require 
proper signaling from the notochord, and it has been 
demonstrated that also the integrity of the perinotochordal 
sheath is essential for the axon projections [46-49].
Transient depletion of fas/fasl resulted, later in 
development, in vertebrae mineralization defects instead 
of the normal notochord ossification [32]. fas/fasl 
loss-of function might alter the proper notochord cells 
disappearance during notochord regression, similarly 
to what happens to the notochord cells in the nucleus 
pulposus of rat [13]. This might cause the mechanical 
weakening of notochord sheath leading to defects in 
vertebrae formation [48]. It is worth to note, that all the 
phenotypic defects we observed are specifically caused by 
a transient fas/fasl-loss-of-function [59]. Our data show 
how transient deregulation of this pathway during embryo 
development can cause a cascade of effects seen much 
later in the larvae and reminiscent of some of chordoma 
characteristics. However, due to the transient condition of 
our loss-of-function we did not obtained a chordoma-like 
tumor in the zebrafish.
In a recent work, a zebrafish model of chordoma 
has been obtained constitutively expressing the HRAS 
pathway [50].
The upregulation of T gene, involved in the 
regulation of cell cycle control, might lead to notochord 
cells proliferation [5, 51]; in alternative we speculated 
that the defects in notochord regression, through apoptosis 
alterations, may maintain proliferating notochord cells 
expressing the T gene, or both these possibilities [7]. 
Neverteless, the evidence here provided indicates the 
early role of FAS/FASL pathway during embryogenesis 
as a possible cause of chordoma formation [57, 58], and 
suggests the need for persistent dysregulation of FAS/
FASL pathway in later stages as a determinant for tumor 
onset. Several mechanisms such as methylation and/or 
post-transcriptional expression modulation by specific 
miRNAs, control the expression of FAS and FASL [52-54]. 
The dysregulation of one or more of those mechanisms 
during development and later in chordoma might be 
the cause of FAS/FASL altered expression. In turn, a 
dysregulation of FAS alternative splicing is caused also by 
the enhanced expression of the anti-apoptotic FAS isoform 
in chordoma [29, 55, 56].
This study provides new insights on notochord 
biology and indicates the implication of Fas/Fasl in 
chordoma, addressing future areas of investigation to 
identify new targets for chordoma treatment and diagnosis.
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MATERIAL AND METHODS
Patients
The cohort includes fourteen SBCs patients 
described for the first time in this study and seventeen 
patients previously reported [25], for a total of thirty-one 
patients with SBC (Table 1), each of whom underwent 
surgery at the Department of Neurosurgery of the San 
Raffaele Hospital in Milan, Italy, between August 
1997 and December 2011. Twenty-three patients 
were males (71.9%), six were females (28.1%); ages 
ranged from 19 to 71 years (average 47, 7 years; SD = 
15.24). Six patients (19%) had been treated previously. 
Table 1: Cohort of patients
Patient Sex Age Histology Recurrence* Death* Description
12 M 67 chondroid - - Riva et al. 2003
13 M 55 classic - - Riva et al. 2003
20 M 55 classic 41 47 Riva et al. 2003
21 M 46 classic - - Riva et al. 2003
22 M 40 classic 22 30 Riva et al. 2003
23 M 56 - - - Riva et al. 2003
24 F 29 chondroid - - Riva et al. 2003
25 M 27 chondroid 24 53 Riva et al. 2003
26 M 52 classic - - Longoni et al. 2008
28 F 69 - - - Longoni et al. 2008
35 F 25 classic - - Longoni et al. 2008
37 F 41 classic - - Longoni et al. 2008
38 M 31 classic - - Longoni et al. 2008
39 F 32 chondroid - - Longoni et al. 2008
40 F 30 chondroid 16 - Longoni et al. 2008
45 M 52 chondroid 5 7 Longoni et al. 2008
47 M 66 - - - This work
49 M 46 classic - - Longoni et al. 2008
51 M 55 classic 36 - This work
53 M 47 chondroid - - This work
54 M nd - - - This work
59 F 69 chondroid - - This work
60 F 61 classica - 0 This work
61 M 65 classica - - This work
62 M 71 classic - - This work
64 M 46 classic - - This work
65 M 49 classic - - This work
66 M 45 - - - This work
68 M 20 - - - This work
69 M 62 - - - This work
71 M 19 classic - - This work
Abbreviations: M, male; F, female; *months after surgery
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The histological specimens were reviewed in each case 
by the same pathologist for the presence of specific 
immunohistochemical markers, diagnostic of chordoma 
(S-100, vimentin, EMA, cytokeratine). The Nuclei 
Pulposi (NP) were obtained after surgical excision of 
intervetebral herniated disks from three young individuals. 
The expression study carried out on the surgical specimens 
did not impact neither the course of surgical operations 
nor the decision about post-operative adjuvant therapies. 
Informed consent for molecular genetic researches on the 
surgical specimens was signed by all the patients before 
operations.
U-CH1 chordoma cell line and treatments
Chordoma cell line U-CH1 was obtained from the 
Chordoma Foundation and it was maintained in IMDM 
(Invitrogen 12440) / RPMI1640 (Sigma-Aldrich Milan, 
Italy) four to one ratio (4:1), supplemented with 10% 
FBS (EuroClone, Milan, Italy) and 100 u/mL penicillin/
streptomycin (Sigma-Aldrich) at 37°C and 5% CO2 [10]. 
The cells were seeded in coated plates or flasks (Collagen 
Cellware Becton DickinsonSan Jose, CA) and treated 
with SuperFAS Ligand (soluble Fasl, Enzo Life Science, 
Farmingdale, NY) at different times and concentrations. 
SuperFAS Ligand was reconstituted with 50 μL sterile 
water to 0.1 mg/mL and stored at -20°C, according to the 
manufacturer’s instructions.
Animals
Breeding zebrafish was maintained at 28°C on a 
14 h light/10 h dark cycle. Embryos were collected by 
natural spawning, staged and raised according to Kimmel 
and colleagues [18], in agreement with EU Directive 
2010/63/EU for animal. We express the embryonic ages 
in somites (s), hours post fertilization (hpf) and days 
post fertilization (dpf). Fish lines were described in 
Supplementary Materials.
RT-PCR
Total RNA from tumor samples was extracted from 
frozen samples by using Trizol reagent (Life Technologies, 
Carlsbad, CA, USA) according to the producer’s 
instructions. Reverse transcription (RT) was carried out 
on 1 μg of total RNA using the iScriptTM cDNA Synthesis 
kit (Bio-Rad Laboratories Inc. Barkeley, CA, USA). The 
specific PCR primers for FAS isoforms were already 
reported [17]. FASL and T specific primers are reported 
in Supplementary Table 1. Total RNA from 17 zebrafish 
samples (an average of 30 embryos/larvae per sample) was 
extracted with the TOTALLY RNA isolation kit (Ambion, 
Life Technologies, Paisley UK), treated with RQ1 RNase-
Free DNase (Promega, Madison WI, USA) and reverse 
transcribed using SuperScript II RT (Life Technologies, 
Carlsbad CA, USA). Primers list in Supplementary 
Table 1.
RT and quantitative real time PCR (qPCR)
RTs were performed using 1 μg of DNase treated 
(DNA-free™, Ambion) total RNA in presence of random 
hexamers (Life Technologies) and SuperScript II reverse 
transcriptase (Life Technologies). qPCRs were carried out 
as reported in Malafoglia [57] and colleagues and also 
Supplementary Materials.
Western blot analysis
The whole proteins extraction was performed on 
fresh/frozen specimens from the new enrolled patients, 
which were disaggregated into a SDS-PAGE sample 
buffer containing protease inhibitors as in Bellipanni and 
colleague [58]. The antibodies (Ab) used and specific 
dilutions are reported in Supplementary Materials.
In situ hybridization, histological analysis and 
immunohistochemistry
Whole mount in situ hybridization (WISH) 
experiments, were carried out as described by Thisse and 
colleagues [59]. Immunohystochemistry was carried out 
as described in Panzer and colleagues [60]. Probes and 
antibodies were described in Supplementary Materials. For 
histological sections, embryos/larvae were re-fixed in 4% 
PFA, dehydrated and stored in methanol, wax embedded, 
sectioned (5-8 μm) and Hematoxilin/Eosin (H/E) stained. 
Images acquirement was described in Supplementary 
Materials.
TUNEL staining
For TUNEL assay, a minimum of 24 embryos 
per treatment were fixed with 4% PFA for 2 h at room 
temperature. Embryos were washed with methanol at 
–20°C and then twice with PBC (0.001% Triton X-100, 
0.1% sodium citrate in PBS) for 10 minutes. Staining 
for apoptotic cells was performed using the In situ Cell 
Death Detection Kit (Roche) according to manufacturers’ 
instructions.
Injections
Injections were carried out on 1- to 2-cell stage 
embryos; the dye tracer rhodamine dextran was also 
co-injected. The PCS2+ plasmid containing twhh:GFP 
construct was kindly provided by J. Du [37] and injected 
at a concentration of 200 pg/embryo. Morpholino 
description and validation was performed as described in 
Supplementary Materials. Morpholino sequences list in 
Supplementary Table 2.
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Sorting
70-100 embryos at 24 and 48 hpf injected with the 
pCS2+ (twhh:GFP) construct, were dissociated and GFP+ 
cells were sorted using a Vantage Sorter SE (Becton-
Dickinson, San Jose CA, USA) at a flow rate of 3000 cells 
per second. GFP was exited at 488 nm using an argon 
laser. Cells dissociated from wild-type embryos were used 
to set the gating to exclude green autofluorescence. RNA 
was extracted from sorted cells with the micro-RNAeasy 
kit (Qiagen, Venlo, Netherlands), retro-transcribed with 
the iSCRIPTtm cDNA synthesis kit (Biorad).
Confocal images
Live ET30:Et(kita:GalTA4,UAS:mCherry)hzm 
trans genic fish were anesthetized in a 0, 5% tricaine 
solution in fish water, mounted in a 1% low melt agarose 
and imaged on a Leica TCS NT confocal microscope.
Calcein staining
Calcein (Sigma-Aldrich, St. Louis MO, USA) 
staining was done according to Du and colleagues [30, 37].
Statistical analysis
For qPCR experiments, data were statistically 
analyzed applying a two-tailed T-test setting p≤0.05 as 
significant. Data were analyzed using the comparative 
ΔΔCt method both t test and SD values refer to samples 
triplicates.
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